Victor G Gian
Overview
Explore the profile of Victor G Gian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spigel D, Burris 3rd H, Greco F, Shih K, Gian V, Lipman A, et al.
Cancer
. 2018 Apr;
124(11):2355-2364.
PMID: 29645086
Background: This study compared the efficacy and safety of treatment with erlotinib plus pazopanib versus erlotinib plus placebo in patients with previously treated advanced non-small cell lung cancer (NSCLC). Methods:...
2.
Spigel D, Rubin M, Gian V, Shipley D, Burris 3rd H, Kosloff R, et al.
Lung Cancer
. 2017 Nov;
113:79-84.
PMID: 29110854
Purpose: To evaluate the efficacy of erlotinib, continued after tumor progression, plus sorafenib versus sorafenib alone in patients with refractory metastatic non-small cell lung cancer (NSCLC) who previously benefitted from...
3.
Hainsworth J, Thompson D, Bismayer J, Gian V, Merritt W, Whorf R, et al.
Cancer Med
. 2015 Jan;
4(5):673-81.
PMID: 25556916
This trial compared the efficacy and toxicity of standard first-line treatment with paclitaxel/carboplatin versus paclitaxel/carboplatin plus sorafenib in patients with advanced ovarian carcinoma. Patients with stage 3 or 4 epithelial...
4.
Spigel D, Greco F, Waterhouse D, Shipley D, Zubkus J, Bury M, et al.
Lung Cancer
. 2012 Sep;
78(1):70-5.
PMID: 22947511
Background: Epothilones, a new class of cytotoxic agents, have demonstrated activity in non-small-cell lung cancer (NSCLC). This phase II study examined ixabepilone/carboplatin (cohort A) and ixabepilone/carboplatin/bevacizumab (cohort B) as first-line...
5.
Spigel D, Hainsworth J, Gandhi J, Gian V, Peyton J, West-Osterfield K, et al.
J Thorac Oncol
. 2010 Jun;
5(6):862-6.
PMID: 20521352
Background: Carboplatin and topotecan are commonly used in the treatment of small cell lung cancer (SCLC); however, there are no data for this combination in the first-line setting using weekly...
6.
Jones S, Greco F, Gian V, Miranda F, Raefsky E, Hainsworth J, et al.
Cancer
. 2005 Sep;
104(9):1985-91.
PMID: 16134182
Background: The current Phase I trial was conducted to determine the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended Phase II dose of oral fixed-dose temozolomide when administered for 5...
7.
Hainsworth J, Mainwaring M, Thomas M, Porter 3rd L, Gian V, Jones S, et al.
Clin Lung Cancer
. 2003 Nov;
4(6):347-55.
PMID: 14599303
To evaluate the feasibility, toxicity, and efficacy of oral gefitinib (ZD1839, Iressa) in patients with refractory non-small-cell lung cancer (NSCLC) treated in a community-based setting. One hundred twenty-four patients with...
8.
Jones S, Gian V, Greco F, Miranda F, Shipley D, Thompson D, et al.
Oncology (Williston Park)
. 2003 Jun;
17(5 Suppl 5):41-5.
PMID: 12800606
This phase I study was conducted to determine the dose-limiting toxicity, maximum tolerated doses, and recommended phase II doses of the combination of irinotecan (CPT-11, Camptosar) and temozolomide (Temodar). Patients...